Celerus Diagnostics Announces Board of Directors; Distinguished Team Brings Diverse Experience to Start-up.

SANTA BARBARA, Calif. -- Celerus Diagnostics, Inc., the cancer diagnostics company focused on rapid tumor testing, today formally announced their Board of Directors whose members include:

--Page Erickson, Chairman and Chief Executive Officer of Celerus

--Michael Sarrasin, Chief Operating Officer of Celerus

--Fred Krupica, CFO of Malibu Biofuels, Inc.

--Dennis Frisman, Senior Pathologist at the Eisenhower Medical Center 

--David Gross, Founder of Fastclick

--Rich Jasen, Director at Savvian's Private Capital Group

--Michael Bell, Founder of Bell Machine and Design

"We are extremely pleased to have such an experienced, diverse Board," said Mr. Erickson. "Each member's unique background, ranging from expertise within the financial markets to lengthy tenures within the pathology and technology arenas, has significantly contributed to our growth and product development."

"It's exciting to be part of a company that is making such incredible headway in improving cancer patient care management," said Mr. Jasen. "The technology will forge the way to faster and more efficient test results."

Founded in 2004, Celerus Diagnostics is designing an instrument that will provide the capability to move results closer to the patient for quicker decision making by the physician. By addressing the unmet needs of the anatomic pathology laboratory, the Celerus diagnostic testing solution will provide "real time" solutions for cancer patient management.

"I'm very pleased to be on the Celerus Board as we build a worldwide competitor in anatomic pathology," said Mr. Krupica. "I've already seen the tremendous capabilities of the management team and intense focus on technology and product development."

"Our Board is comprised of Directors with extensive real world experience," added Mr. Erickson. "Each member is extremely valuable and is contributing their guidance and knowledge to our dynamic team of medical industry experts. We are honored to welcome each of them to the team."

About Celerus:

Founded in 2004 in Santa Barbara, California, Celerus Diagnostics is committed to enhancing the diagnostic capabilities of the pathology laboratory. Celerus technology provides the capability to decentralize testing, and move results closer to the patient for real time decision making. For more information, please visit our website: www.celerusdiagnostics.com or contact us at 805.685.0797.

This release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, Celerus Diagnostics' ability to successfully complete its development program, competitive pressures and other factors such as the introduction or regulatory approval of new products by our competitors and pricing of competing products and the resulting effects on sales and pricing of our products, disruptions or other problems with our sources of supply, significant product liability or other claims, difficulties with new product development and market acceptance, changes in the mix of our products sold, patent conflicts, product recalls, United States Food and Drug Administration (FDA) delay in or approval or rejection of new or existing products, changes in Medicare, Medicaid or third-party reimbursement policies, changes in government regulation, use of hazardous or environmentally sensitive materials, our inability to implement new information technology systems, our inability to integrate new acquisitions, and other events. This press release reflects information as of the date of this press release, and the company takes no responsibility in updating the information contained herein now or in the future.